We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
Read MoreHide Full Article
We issued an updated report on Epizyme Inc. on Aug 14.
The company’s lead pipeline candidate is tazemetostat, a first-in-class EZH2 inhibitor, which is currently being evaluated for the treatment of solid tumors and hematological malignancies as a monotherapy and to treat relapsed and front-line disease as a combination therapy.
Epizyme’s NDA for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally-advanced epithelioid sarcoma (ES), who are not eligible for curative surgery, was accepted by the FDA for priority review in July 2019. The FDA is expected to give its decision on Jan 23, 2020. If approved, tazemetostat will be the first commercially available EZH2 inhibitor and the first treatment specifically indicated for epithelioid sarcoma patients. A potential approval will significantly boost the growth prospects
The company also plans to submit an NDA for accelerated approval of tazemetostat in patients with follicular lymphoma (FL), regardless of their EZH2 mutational status, who have been previously treated with two or more systemic therapies. The company expects to submit the NDA for accelerated approval in the fourth quarter of 2019.
Epizyme is planning to initiate multiple clinical studies to evaluate tazemetostat in earlier treatment lines of follicular lymphoma, and explore new combinations and potential indications in both FL and solid tumors.
The company also intends to discover the potential of tazemetostat in earlier lines of FL as combination therapy. It is planning to conduct a confirmatory program with an adaptive study evaluating the combination of tazemetostat and the chemo-free treatment regimen “R2” [Celgene’s Revlimid plus Roche’s (RHHBY - Free Report) Rituxan] in the second line or later treatment setting for FL patients, both with and without EZH2 activating mutations. The final design is subject to alignment with the FDA and the company expects to initiate the safety run-in portion in the second half of 2019.
Epizyme also aims at completing IND-enabling studies on EZM8266, its G9a inhibitor designed to treat patients with sickle cell disease (SCD). It is on track to begin clinical development of the candidate in the second half of 2019 with a dose-finding and safety study.
Epizyme’s proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). However, the company faces competition from companies like Glaxo, Novartis (NVS - Free Report) , Pfizer and Constellation, which are developing new epigenetic treatments for cancer targeting HMTs.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
We issued an updated report on Epizyme Inc. on Aug 14.
The company’s lead pipeline candidate is tazemetostat, a first-in-class EZH2 inhibitor, which is currently being evaluated for the treatment of solid tumors and hematological malignancies as a monotherapy and to treat relapsed and front-line disease as a combination therapy.
Epizyme’s NDA for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally-advanced epithelioid sarcoma (ES), who are not eligible for curative surgery, was accepted by the FDA for priority review in July 2019. The FDA is expected to give its decision on Jan 23, 2020. If approved, tazemetostat will be the first commercially available EZH2 inhibitor and the first treatment specifically indicated for epithelioid sarcoma patients. A potential approval will significantly boost the growth prospects
The company also plans to submit an NDA for accelerated approval of tazemetostat in patients with follicular lymphoma (FL), regardless of their EZH2 mutational status, who have been previously treated with two or more systemic therapies. The company expects to submit the NDA for accelerated approval in the fourth quarter of 2019.
Epizyme is planning to initiate multiple clinical studies to evaluate tazemetostat in earlier treatment lines of follicular lymphoma, and explore new combinations and potential indications in both FL and solid tumors.
The company also intends to discover the potential of tazemetostat in earlier lines of FL as combination therapy. It is planning to conduct a confirmatory program with an adaptive study evaluating the combination of tazemetostat and the chemo-free treatment regimen “R2” [Celgene’s Revlimid plus Roche’s (RHHBY - Free Report) Rituxan] in the second line or later treatment setting for FL patients, both with and without EZH2 activating mutations. The final design is subject to alignment with the FDA and the company expects to initiate the safety run-in portion in the second half of 2019.
Epizyme also aims at completing IND-enabling studies on EZM8266, its G9a inhibitor designed to treat patients with sickle cell disease (SCD). It is on track to begin clinical development of the candidate in the second half of 2019 with a dose-finding and safety study.
Epizyme’s proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). However, the company faces competition from companies like Glaxo, Novartis (NVS - Free Report) , Pfizer and Constellation, which are developing new epigenetic treatments for cancer targeting HMTs.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>